D-peptide hydrogels as a long-acting multipurpose drug delivery platform for combined contraception and HIV prevention

被引:1
|
作者
Pentlavalli, Sreekanth [1 ]
Coulter, Sophie M. [1 ]
An, Yuming [1 ]
Cross, Emily R. [1 ]
Sun, Han [1 ]
Moore, Jessica, V [1 ]
Bin Sabri, Akmal [1 ]
Greer, Brett [2 ]
Vora, Lalitkumar [1 ]
Mccarthy, Helen O. [1 ]
Laverty, Garry [1 ]
机构
[1] Queens Univ Belfast, Med Biol Ctr, Sch Pharm, 97 Lisburn Rd, Belfast BT9 7BL, North Ireland
[2] Sch Biol Sci, Biol Sci Bldg, 19 Chlorine Gardens, Belfast BT9 5DL, North Ireland
基金
英国工程与自然科学研究理事会; 英国惠康基金;
关键词
Long-acting injectable; Peptide hydrogel; Sustained release; HIV/AIDS; Contraception; Enzyme instructed self-assembly; Multipurpose prevention technologies; MICROARRAY PATCHES; IN-VITRO; CABOTEGRAVIR; MICRONEEDLES; DEGRADATION; DESIGN; WOMEN; ACIDS;
D O I
10.1016/j.jconrel.2024.12.052
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
New multipurpose prevention technology products for use by women, focused on reducing HIV infection and preventing unwanted pregnancies, are a global health priority. Discreet long-acting formulations will empower women with greater choice around their sexual health. This paper outlines the development of a long-acting technology that enables multiple drugs to be incorporated within one injectable platform. This fixed-dose combination product is formed from a phosphorylated D-peptide (naphthalene-2-ly)-acetyl-diphenylalaninelysine-tyrosine-glycine-OH (Napffky(p)G-OH) that enables the highly hydrophobic drugs MIV-150 (HIV antiretroviral) and etonogestrel (contraceptive) to be solubilized together within aqueous solvents. Upon subcutaneous injection, this D-peptide-drug combination self-assembles in response to phosphatase enzymes present within the skin space to form an in situ forming drug-releasing hydrogel depot. Oscillatory rheology confirmed the formation of hydrogels, which began within 10 s exposure to 3.98 U/mL phosphatase enzymes and continued for 198 mins for a Napffk(MIV-150)y(p)G-OH + Napffk(ENG)y(p)G-OH combination (8:2 ratio). Biostability against proteases, an important consideration for long-acting injectables, was demonstrated for at least 28 days in vitro. Covalent attachment of each drug to the D-peptide via an ester linkage enabled sustained release of the drug in an unmodified form via hydrolysis of the D-peptide-drug linker. This significantly reduced the initial drug burst. Low toxicity was also demonstrated in vitro via cell culture (MTS, LHS, Live/Dead (R)) and within in vivo studies (H&E staining). The fixed dose combination was able to deliver clinically relevant concentrations of each drug to Sprague-Dawley rats for at least 49 days, providing proof-of-concept for the use of hydrogel-forming D-peptides (Napffky(p)G-OH) as a long-acting injectable platform for the delivery of multiple hydrophobic drugs.
引用
收藏
页码:30 / 44
页数:15
相关论文
共 16 条
  • [1] Enzyme-Triggered l-α/d-Peptide Hydrogels as a Long-Acting Injectable Platform for Systemic Delivery of HIV/AIDS Drugs
    Coulter, Sophie M.
    Pentlavalli, Sreekanth
    Vora, Lalitkumar K.
    An, Yuming
    Cross, Emily R.
    Peng, Ke
    McAulay, Kate
    Schweins, Ralf
    Donnelly, Ryan F.
    McCarthy, Helen O.
    Laverty, Garry
    ADVANCED HEALTHCARE MATERIALS, 2023, 12 (18)
  • [2] Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy
    Young, Isabella C.
    Pallerla, Aryani
    Cottrell, Mackenzie L.
    Maturavongsadit, Panita
    Prasher, Alka
    Shrivastava, Roopali
    Cruz, Gabriela De la
    Montgomery, Stephanie A.
    Schauer, Amanda
    Sykes, Craig
    Kashuba, Angela D. M.
    Benhabbour, S. Rahima
    JOURNAL OF CONTROLLED RELEASE, 2023, 363 : 606 - 620
  • [3] Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention
    Krovi, Sai Archana
    Johnson, Leah M.
    Luecke, Ellen
    Achilles, Sharon L.
    van der Straten, Ariane
    ADVANCED DRUG DELIVERY REVIEWS, 2021, 176
  • [4] Co-delivery of an HIV prophylactic and contraceptive using PGSU as a long-acting multipurpose prevention technology
    Cohen, Jarrod
    Shull, Dennis
    Reed, Stephanie
    EXPERT OPINION ON DRUG DELIVERY, 2023, 20 (02) : 285 - 299
  • [5] The importance of the "how": the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment
    Grimsrud, Anna
    Wilkinson, Lynne
    Delany-Moretlwe, Sinead
    Ehrenkranz, Peter
    Green, Kimberly
    Murenga, Maureen
    Ngure, Kenneth
    Otwoma, Nelson J.
    Phanuphak, Nittaya
    Vandevelde, Wim
    Vitoria, Marco
    Bygrave, Helen
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26
  • [6] A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
    Bares, Sara H.
    Scarsi, Kimberly K.
    CURRENT OPINION IN HIV AND AIDS, 2022, 17 (01) : 22 - 31
  • [7] Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations
    Mgodi, Nyaradzo M.
    Murewanhema, Grant
    Moyo, Enos
    Samba, Chesterfield
    Musuka, Godfrey
    Dzinamarira, Tafadzwa
    Brown, Joelle M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26
  • [8] Quality by design thinking in the development of long-acting injectable PLGA/PLA-based microspheres for peptide and protein drug delivery
    Zhang, Chengqian
    Yang, Liang
    Wan, Feng
    Bera, Hriday
    Cun, Dongmei
    Rantanen, Jukka
    Yang, Mingshi
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 585
  • [9] Delivery of Islatravir via High Drug-Load, Long-acting Microarray Patches for the Prevention or Treatment of Human Immunodeficiency Virus
    Anjani, Qonita Kurnia
    Johnson, Ashley R.
    Sabri, Akmal H.
    Lutz, Ryan
    Tignor, Steven
    Ballard, Jeanine
    Rudd, Nathan
    Zhao, Li
    Vora, Lalitkumar K.
    Barrett, Stephanie E.
    Wagner, Angela
    Donnelly, Ryan F.
    ADVANCED HEALTHCARE MATERIALS, 2025,
  • [10] A Bilayer Microarray Patch (MAP) for HIV Pre-Exposure Prophylaxis: The Role of MAP Designs and Formulation Composition in Enhancing Long-Acting Drug Delivery
    Vora, Lalitkumar K.
    Tekko, Ismaiel A.
    Zanutto, Fabiana Volpe
    Sabri, Akmal
    Choy, Robert K. M.
    Mistilis, Jessica
    Kwarteng, Priscilla
    Jarrahian, Courtney
    McCarthy, Helen O.
    Donnelly, Ryan F.
    PHARMACEUTICS, 2024, 16 (01)